Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Change in Receivables (2016 - 2025)

Spero Therapeutics' Change in Receivables history spans 10 years, with the latest figure at -$1.6 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 501.8% year-over-year to -$1.6 million; the TTM value through Dec 2025 reached -$3.1 million, down 298.51%, while the annual FY2025 figure was -$3.1 million, 298.51% down from the prior year.
  • Change in Receivables reached -$1.6 million in Q4 2025 per SPRO's latest filing, down from -$869000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $3.5 million in Q1 2024 to a low of -$6.7 million in Q2 2021.
  • Average Change in Receivables over 5 years is -$282650.0, with a median of -$122500.0 recorded in 2021.
  • Peak YoY movement for Change in Receivables: tumbled 1202.29% in 2023, then skyrocketed 733.22% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $38000.0 in 2021, then surged by 244.74% to $131000.0 in 2022, then crashed by 1202.29% to -$1.4 million in 2023, then skyrocketed by 126.94% to $389000.0 in 2024, then crashed by 501.8% to -$1.6 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Change in Receivables are -$1.6 million (Q4 2025), -$869000.0 (Q3 2025), and $1.8 million (Q2 2025).